A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01649336 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions

DRUG: MEK162, MEK inhibitor; oral
DRUG: Paclitaxel, mitotic inhibitor; intravenous

Sponsor

Array Biopharma, now a wholly owned subsidiary of Pfizer